Ken Duncan, Ph.D., joined the Gates Foundation in 2007, where he leads the drug discovery program in tuberculosis (TB), malaria, antivirals, and contraception. He established the TB Drug Accelerator to facilitate collaboration across industry, academia, and non-profit teams to speed up drug discovery research. He played a major role in launching the Global Health Drug Discovery Institute in Beijing, China. Dr. Duncan currently serves on the Selection Committee of the Global Health Innovative Technology Fund in Japan and is a member of the Governing Board of the Tres Cantos Open Lab Foundation in Spain. Before joining the foundation, Dr. Duncan spent 16 years at GSK, most recently as Director, Diseases of the Developing World, and two years as a consultant and as a project manager at Imperial College London.
Dr. Duncan has a Bachelor of Science degree in Molecular Biology from the University of Edinburgh, a Ph.D. from the University of Glasgow and carried out postdoctoral research at MIT and Harvard Medical School.